Search

Your search keyword '"Zelniker, Thomas A."' showing total 187 results
Start Over Author "Zelniker, Thomas A." Search Limiters Available in Library Collection
187 results on '"Zelniker, Thomas A."'

1. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome

Author

Gyöngyösi, Mariann, Lukovic, Dominika, Mester-Tonczar, Julia, Zlabinger, Katrin, Einzinger, Patrick, Spannbauer, Andreas, Schweiger, Victor, Schefberger, Katharina, Samaha, Eslam, Bergler-Klein, Jutta, Riesenhuber, Martin, Nitsche, Christian, Hengstenberg, Christian, Mucher, Patrick, Haslacher, Helmuth, Breuer, Monika, Strassl, Robert, Puchhammer-Stöckl, Elisabeth, Loewe, Christian, Beitzke, Dietrich, Hasimbegovic, Ena, and Zelniker, Thomas A.

Published
2023
Full Text
View/download PDF

9. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Author

Schechter, Meir, Wiviott, Stephen D., Raz, Itamar, Goodrich, Erica L., Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina, Zelniker, Thomas A., Fredriksson, Martin, Johansson, Peter A, Leiter, Lawrence A., Bhatt, Deepak, McGuire, Darren K, Wilding, John P. H., Gause-Nilson, Ingrid A. M., Cahn, Avivit, Langkilde, Anna Maria, Sabatine, Marc S., and Mosenzon, Ofri

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

BackgroundIn people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less is known about their effects on hospitalisation from any cause, especially in people with type 2 diabetes without atherosclerotic cardiovascular disease, which includes most of the global population of people with type 2 diabetes. We aimed to assess the effect of the SGLT2 inhibitor, dapagliflozin, on the risks of hospitalisations for any cause and for specific causes in people with type 2 diabetes with and without atherosclerotic cardiovascular disease.MethodsThe DECLARE-TIMI 58 trial was a double-blind, multicentre, randomised, placebo-controlled study. People with type 2 diabetes and either risk factors for or established atherosclerotic cardiovascular disease were randomly assigned (1:1) to receive oral dapagliflozin 10 mg or placebo once daily. In these post-hoc analyses, the effects of dapagliflozin on risks of first non-elective any-cause and cause-specific hospitalisation were assessed with Cox proportional hazards regression models overall and in the subset of participants without prevalent atherosclerotic cardiovascular disease. The risk of total (first plus subsequent) non-elective hospitalisations was assessed with Lin-Wei-Ying-Yang model. Investigator-reported System Organ Class terms were used to classify cause-specific hospitalisations. The trial is registered with ClinicalTrials.gov, NCT01730534.FindingsBetween April 25, 2013, and Sept 18, 2018, 17 160 people (6422 [37·4%] women, 10 738 [62·6%] men; mean age 63·9 years [SD 6·8]) were enrolled in the original trial, of whom 10186 (59·4%) had multiple risk factors for but did not have established atherosclerotic cardiovascular disease, and 6835 (39·8%) had both no evidence of atherosclerotic cardiovascular disease and low KDIGO risk. Over a median follow-up of 4·2 years (IQR 3·9–4·4), dapagliflozin was associated with a lower risk of first non-elective hospitalisation for any cause (2779 [32·4%] of 8582 people in the dapagliflozin group vs 3036 [35·4%] of 8578 people in the placebo group; hazard ratio [HR] 0·89 [95% CI 0·85–0·94]) and total (first plus subsequent) non-elective hospitalisations for any cause (risk ratio 0·92 [95% CI 0·86–0·97]). The association between dapagliflozin use and the risk of first non-elective hospitalisation for any cause was consistent in subgroups of participants with (HR 0·92 [95% CI 0·85–0·99] and without (0·87 [0·81–0·94]) atherosclerotic cardiovascular disease at baseline (p interaction=0·31). Compared with the placebo group, the dapagliflozin group had lower risk of first hospitalisations due to cardiac disorders (HR 0·91 [95% CI 0·84–1·00]), metabolism and nutrition disorders (0·73 [0·60–0·89]), renal and urinary disorders (0·61 [0·49–0·77]), and due to any other cause excluding these three causes (0·90 [0·85–0·96]). Treatment with dapagliflozin was also associated with a lower risk of hospitalisations due to musculoskeletal and connective tissue disorders (HR 0·81 [0·67–0·99]) and infections and infastations (HR 0·86 [0·78–0·96]).InterpretationDapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on health-care costs attributable this condition.

Published
2023

13. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

Author

Zelniker, Thomas A, Morrow, David A, Mosenzon, ofri, Goodrich, Erica, Jarolim, Petr, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Averkov, Oleg V, Budaj, Andrzej, Parkhomenko, Alexander, Ray, Kausik K, Gause-nilsson, Ingrid A, Langkilde, Anna Maria, Fredriksson, Martin, RAZ, Itamar, Sabatine, Marc S, and Wiviott, Stephen D

Published
2020
Full Text
View/download PDF

16. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

Author

Bonaca, Marc P., Wiviott, Stephen D., Zelniker, Thomas A., Mosenzon, Ofri, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Goodrich, Erica L., De Mendonca Furtado, Remo Holanda, Wilding, John P.H., Cahn, Avivit, Gause-Nilsson, Ingrid A.M., Johanson, Per, Fredriksson, Martin, Johansson, Peter A., Langkilde, Anna Maria, Raz, Itamar, and Sabatine, Marc S.

Published
2020
Full Text
View/download PDF

17. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Author

Zelniker, Thomas A., Bonaca, Marc P., Furtado, Remo H.M., Mosenzon, Ofri, Kuder, Julia F., Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Budaj, Andrzej, Kiss, Robert G., Padilla, Francisco, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2020
Full Text
View/download PDF

18. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery

Author

Hofer, Felix, primary, Hammer, Andreas, additional, Pailer, Ulrike, additional, Koller, Lorenz, additional, Kazem, Niema, additional, Steinacher, Eva, additional, Steinlechner, Barbara, additional, Andreas, Martin, additional, Laufer, Günther, additional, Wojta, Johann, additional, Zelniker, Thomas A., additional, Hengstenberg, Christian, additional, Niessner, Alexander, additional, and Sulzgruber, Patrick, additional

Published
2023
Full Text
View/download PDF

19. Coronary Angiography after Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation:One-Year Outcomes of a Randomized Clinical Trial

Author

Desch, Steffen, Freund, Anne, Akin, Ibrahim, Behnes, Michael, Preusch, Michael R., Zelniker, Thomas A., Skurk, Carsten, Landmesser, Ulf, Graf, Tobias, Eitel, Ingo, Fuernau, Georg, Haake, Hendrik, Nordbeck, Peter, Hammer, Fabian, Felix, Stephan B., Hassager, Christian, Kjærgaard, Jesper, Fichtlscherer, Stephan, Ledwoch, Jakob, Lenk, Karsten, Joner, Michael, Steiner, Stephan, Liebetrau, Christoph, Voigt, Ingo, Zeymer, Uwe, Brand, Michael, Schmitz, Roland, Horstkotte, Jan, Jacobshagen, Claudius, Pöss, Janine, Abdel-Wahab, Mohamed, Lurz, Philipp, Jobs, Alexander, De Waha, Suzanne, Olbrich, Denise, Sandig, Frank, König, Inke R., Brett, Sabine, Vens, Maren, Klinge, Kathrin, Thiele, Holger, Desch, Steffen, Freund, Anne, Akin, Ibrahim, Behnes, Michael, Preusch, Michael R., Zelniker, Thomas A., Skurk, Carsten, Landmesser, Ulf, Graf, Tobias, Eitel, Ingo, Fuernau, Georg, Haake, Hendrik, Nordbeck, Peter, Hammer, Fabian, Felix, Stephan B., Hassager, Christian, Kjærgaard, Jesper, Fichtlscherer, Stephan, Ledwoch, Jakob, Lenk, Karsten, Joner, Michael, Steiner, Stephan, Liebetrau, Christoph, Voigt, Ingo, Zeymer, Uwe, Brand, Michael, Schmitz, Roland, Horstkotte, Jan, Jacobshagen, Claudius, Pöss, Janine, Abdel-Wahab, Mohamed, Lurz, Philipp, Jobs, Alexander, De Waha, Suzanne, Olbrich, Denise, Sandig, Frank, König, Inke R., Brett, Sabine, Vens, Maren, Klinge, Kathrin, and Thiele, Holger

Abstract

Importance: Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest (OHCA). The long-term effect of early coronary angiography on patients with OHCA with possible coronary trigger but no ST-segment elevation remains unclear. Objective: To compare the clinical outcomes of early unselective angiography with the clinical outcomes of a delayed or selective approach for successfully resuscitated patients with OHCA of presumed cardiac origin without ST-segment elevation at 1-year follow-up. Design, Setting, and Participants: The TOMAHAWK trial was a multicenter, international (Germany and Denmark), investigator-initiated, open-label, randomized clinical trial enrolling 554 patients between November 23, 2016, to September 20, 2019. Patients with stable return of spontaneous circulation after OHCA of presumed cardiac origin but without ST-segment elevation on the postresuscitation electrocardiogram were eligible for inclusion. A total of 554 patients were randomized to either immediate coronary angiography after hospital admission or an initial intensive care assessment with delayed or selective angiography after a minimum of 24 hours. All 554 patients were included in survival analyses during the follow-up period of 1 year. Secondary clinical outcomes were assessed only for participants alive at 1 year to account for the competing risk of death. Interventions: Early vs delayed or selective coronary angiography and revascularization if indicated. Main Outcomes and Measures: Evaluations in this secondary analysis included all-cause mortality after 1 year, as well as severe neurologic deficit, myocardial infarction, and rehospitalization for congestive heart failure in survivors at 1 year. Results: A total of 281 patients were randomized to the immediate angiography group and 273 to the delayed or selective group, with a median age of 70 years (IQR, 60-78 years). A total of 369 of 530 patients (69.6%) were male, and 268 of 483 patients (55.5%) had a sho

Published
2023

20. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Author

Kato, Eri T., Silverman, Michael G., Mosenzon, Ofri, Zelniker, Thomas A., Cahn, Avivit, Furtado, Remo H.M., Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Bonaca, Marc P., Ruff, Christian T., Desai, Akshay S., Goto, Shinya, Johansson, Peter A., Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

21. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

Author

Furtado, Remo H.M., Bonaca, Marc P., Raz, Itamar, Zelniker, Thomas A., Mosenzon, Ofri, Cahn, Avivit, Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Ruff, Christian T., Nicolau, Jose C., Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Langkilde, Anna Maria, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

22. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Author

Zelniker, Thomas A., Wiviott, Stephen D., Raz, Itamar, Im, KyungAh, Goodrich, Erica L., Furtado, Remo H.M., Bonaca, Marc P., Mosenzon, Ofri, Kato, Eri T., Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., and Sabatine, Marc S.

Published
2019
Full Text
View/download PDF

23. Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria

Author

Riesenhuber, Martin, primary, Nitsche, Christian, additional, Binder, Christoph J, additional, Schernhammer, Eva S, additional, Stamm, Tanja, additional, Jakse, Friedrich, additional, Anwari, Elaaha, additional, Hamidi, Fardin, additional, Haslacher, Helmuth, additional, Perkmann, Thomas, additional, Hengstenberg, Christian, additional, and Zelniker, Thomas A, additional

Published
2023
Full Text
View/download PDF

25. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction

Author

Furtado, Remo H.M., primary, Juliasz, Marcela G., additional, Chiu, Felipe Y.J., additional, Bastos, Livia B.C., additional, Dalcoquio, Talia F., additional, Lima, Felipe G., additional, Rosa, Renato, additional, Caporrino, Cesar A., additional, Bertolin, Adriadne, additional, Genestreti, Paulo R.R., additional, Ribeiro, Andre S., additional, Andrade, Maria Carolina, additional, Giraldez, Roberto R.C.V., additional, Baracioli, Luciano M., additional, Zelniker, Thomas A., additional, and Nicolau, Jose C., additional

Published
2022
Full Text
View/download PDF

26. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Author

Mosenzon, Ofri, primary, Raz, Itamar, additional, Wiviott, Stephen D., additional, Schechter, Meir, additional, Goodrich, Erica L., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Murphy, Sabina A., additional, Zelniker, Thomas A., additional, Langkilde, Anna Maria, additional, Gause-Nilsson, Ingrid A.M., additional, Fredriksson, Martin, additional, Johansson, Peter A., additional, Wilding, John P.H., additional, McGuire, Darren K., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, Cahn, Avivit, additional, Dwyer, Jamie P., additional, Heerspink, Hiddo J.L., additional, and Sabatine, Marc S., additional

Published
2022
Full Text
View/download PDF

29. Relationship of diabetes, heart failure, and N‐terminal pro‐B‐type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation

Author

Hofer, Felix, primary, Pailer, Ulrike, additional, Sulzgruber, Patrick, additional, Gerges, Christian, additional, Winter, Max‐Paul, additional, Giugliano, Robert P., additional, Gottsauner‐Wolf, Michael, additional, Hülsmann, Martin, additional, Kazem, Niema, additional, Koller, Lorenz, additional, Schönbauer, Robert, additional, Niessner, Alexander, additional, Hengstenberg, Christian, additional, and Zelniker, Thomas A., additional

Published
2022
Full Text
View/download PDF

30. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.

Author

Furtado, Remo H.M., Juliasz, Marcela G., Chiu, Felipe Y.J., Bastos, Livia B.C., Dalcoquio, Talia F., Lima, Felipe G., Rosa, Renato, Caporrino, Cesar A., Bertolin, Adriadne, Genestreti, Paulo R.R., Ribeiro, Andre S., Andrade, Maria Carolina, Giraldez, Roberto R.C.V., Baracioli, Luciano M., Zelniker, Thomas A., and Nicolau, Jose C.

Subjects
ACUTE coronary syndrome, VENTRICULAR ejection fraction, MORTALITY risk factors, HOSPITAL admission & discharge
Abstract

Aims: Left ventricular ejection fraction (LVEF) ≤ 40% is a well‐established risk factor for mortality after acute coronary syndromes (ACS). However, the long‐term prognostic impact of mildly reduced ejection fraction (EF) (LVEF 41–49%) after ACS remains less clear. Methods and results: This was a retrospective study enrolling patients admitted with ACS included in a single‐centre databank. LVEF was assessed by echocardiography during index hospitalization. Patients were divided in the following categories according to LVEF: normal (LVEF ≥ 50%), mildly reduced (LVEF 41–49%), and reduced (LVEF ≤ 40%). The endpoint of interest was all‐cause death after hospital discharge. A multivariable Cox model was used to adjust for confounders. A total of 3200 patients were included (1952 with normal EF, 375 with mildly reduced EF, and 873 with reduced EF). The estimated cumulative incidence rates of mortality at 10 years for patients with normal, mildly reduced, and reduced EF were 24.8%, 33.5%, and 41.3%, respectively. After adjustments, the presence of reduced EF was associated with higher mortality compared with normal EF [adjusted hazard ratio (HR) 1.64; 95% confidence interval (CI) 1.36–1.96; P < 0.001], as was mildly reduced EF compared with normal EF (adjusted HR 1.33; 95% CI 1.05–1.68; P = 0.019). The presence of reduced EF was not associated with a statistically significantly higher mortality compared with mildly reduced EF (adjusted HR 1.23; 95% CI 0.96–1.57; P = 0.095). Conclusions: In patients with ACS, mildly reduced EF measured in the acute phase was associated with higher long‐term mortality compared with patients with normal EF. These data emphasize the importance of anti‐remodelling therapies for ACS patients who have LVEF in the mildly reduced range. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention

Author

Furtado, Remo H.M., primary, Fagundes, Antônio Aurélio, additional, Oyama, Kazuma, additional, Zelniker, Thomas A., additional, Tang, Minao, additional, Kuder, Julia F., additional, Murphy, Sabina A., additional, Hamer, Andrew, additional, Wang, Huei, additional, Keech, Anthony C., additional, Giugliano, Robert P., additional, Sabatine, Marc S., additional, and Bergmark, Brian A., additional

Published
2022
Full Text
View/download PDF

32. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials

Author

Aggarwal, Devika, primary, Bhatia, Kirtipal, additional, Chunawala, Zainali S, additional, Furtado, Remo H M, additional, Mukherjee, Debabrata, additional, Dixon, Simon R, additional, Jain, Vardhmaan, additional, Arora, Sameer, additional, Zelniker, Thomas A, additional, Navarese, Eliano P, additional, Mishkel, Gregory J, additional, Lee, Cheong J, additional, Banerjee, Subhash, additional, Bangalore, Sripal, additional, Levisay, Justin P, additional, Bhatt, Deepak L, additional, Ricciardi, Mark J, additional, and Qamar, Arman, additional

Published
2022
Full Text
View/download PDF

33. Abstract 13729: Monotherapy With a P2Y12 Inhibitor versus Aspirin for Secondary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) Events: A Meta-Analysis of Randomized Trials

Author

Chunawala, Zainali, primary, Aggarwal, Devika, additional, Bhatia, Kirtipal S, additional, jain, vardhmaan, additional, Mukherjee, Debabrata, additional, Baber, Usman, additional, Bangalore, Sripal, additional, NAVARESE, ELIANO, additional, Levisay, Justin p, additional, Mishkel, Gregory, additional, Ricciardi, Mark, additional, Vaduganathan, Muthiah, additional, Furtado, Remo, additional, Zelniker, Thomas A, additional, and Qamar, Arman, additional

Published
2021
Full Text
View/download PDF

34. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

Author

Berg, David D., primary, Wiviott, Stephen D., additional, Scirica, Benjamin M., additional, Zelniker, Thomas A., additional, Goodrich, Erica L., additional, Jarolim, Petr, additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P.H., additional, Johanson, Per, additional, Langkilde, Anna Maria, additional, Raz, Itamar, additional, Braunwald, Eugene, additional, Sabatine, Marc S., additional, and Morrow, David A., additional

Published
2021
Full Text
View/download PDF

35. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Author

Mosenzon, Ofri, primary, Wiviott, Stephen D., additional, Heerspink, Hiddo J.L., additional, Dwyer, Jamie P., additional, Cahn, Avivit, additional, Goodrich, Erica L., additional, Rozenberg, Aliza, additional, Schechter, Meir, additional, Yanuv, Ilan, additional, Murphy, Sabina A., additional, Zelniker, Thomas A., additional, Gause-Nilsson, Ingrid A.M., additional, Langkilde, Anna Maria, additional, Fredriksson, Martin, additional, Johansson, Peter A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P.H., additional, Sabatine, Marc S., additional, and Raz, Itamar, additional

Published
2021
Full Text
View/download PDF

36. BIOMARKER PREDICTION OF MAJOR CORONARY EVENTS AND COMPLEX REVASCULARIZATION PROCEDURES IN PATIENTS WITH STABLE ATHEROSCLEROSIS

Author

Fagundes, Antonio, primary, Morrow, David, additional, Oyama, Kazuma, additional, Furtado, Remo, additional, Zelniker, Thomas, additional, Tang, Minao, additional, Kuder, Julia, additional, Murphy, Sabina A., additional, Hamer, Andrew, additional, Keech, Anthony, additional, Sever, Peter, additional, Giugliano, Robert, additional, Sabatine, Marc, additional, and Bergmark, Brian, additional

Published
2021
Full Text
View/download PDF

37. Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation

Author

Desch, Steffen, Freund, Anne, Akin, Ibrahim, Behnes, Michael, Preusch, Michael R., Zelniker, Thomas A., Skurk, Carsten, Landmesser, Ulf, Graf, Tobias, Eitel, Ingo, Fuernau, Georg, Haake, Hendrik, Nordbeck, Peter, Hammer, Fabian, Felix, Stephan B., Hassager, Christian, Engstrom, Thomas, Fichtlscherer, Stephan, Ledwoch, Jakob, Lenk, Karsten, Joner, Michael, Steiner, Stephan, Liebetrau, Christoph, Voigt, Ingo, Zeymer, Uwe, Brand, Michael, Schmitz, Roland, Horstkotte, Jan, Jacobshagen, Claudius, Poss, Janine, Abdel-Wahab, Mohamed, Lurz, Philipp, Jobs, Alexander, de Waha-Thiele, Suzanne, Olbrich, Denise, Sandig, Frank, Koenig, Inke R., Brett, Sabine, Vens, Maren, Klinge, Kathrin, Thiele, Holger, Desch, Steffen, Freund, Anne, Akin, Ibrahim, Behnes, Michael, Preusch, Michael R., Zelniker, Thomas A., Skurk, Carsten, Landmesser, Ulf, Graf, Tobias, Eitel, Ingo, Fuernau, Georg, Haake, Hendrik, Nordbeck, Peter, Hammer, Fabian, Felix, Stephan B., Hassager, Christian, Engstrom, Thomas, Fichtlscherer, Stephan, Ledwoch, Jakob, Lenk, Karsten, Joner, Michael, Steiner, Stephan, Liebetrau, Christoph, Voigt, Ingo, Zeymer, Uwe, Brand, Michael, Schmitz, Roland, Horstkotte, Jan, Jacobshagen, Claudius, Poss, Janine, Abdel-Wahab, Mohamed, Lurz, Philipp, Jobs, Alexander, de Waha-Thiele, Suzanne, Olbrich, Denise, Sandig, Frank, Koenig, Inke R., Brett, Sabine, Vens, Maren, Klinge, Kathrin, and Thiele, Holger

Abstract

BackgroundMyocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits of early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence of ST-segment elevation are unclear.MethodsIn this multicenter trial, we randomly assigned 554 patients with successfully resuscitated out-of-hospital cardiac arrest of possible coronary origin to undergo either immediate coronary angiography (immediate-angiography group) or initial intensive care assessment with delayed or selective angiography (delayed-angiography group). All the patients had no evidence of ST-segment elevation on postresuscitation electrocardiography. The primary end point was death from any cause at 30 days. Secondary end points included a composite of death from any cause or severe neurologic deficit at 30 days.ResultsA total of 530 of 554 patients (95.7%) were included in the primary analysis. At 30 days, 143 of 265 patients (54.0%) in the immediate-angiography group and 122 of 265 patients (46.0%) in the delayed-angiography group had died (hazard ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.63; P=0.06). The composite of death or severe neurologic deficit occurred more frequently in the immediate-angiography group (in 164 of 255 patients [64.3%]) than in the delayed-angiography group (in 138 of 248 patients [55.6%]), for a relative risk of 1.16 (95% CI, 1.00 to 1.34). Values for peak troponin release and for the incidence of moderate or severe bleeding, stroke, and renal-replacement therapy were similar in the two groups.ConclusionsAmong patients with resuscitated out-of-hospital cardiac arrest without ST-segment elevation, a strategy of performing immediate angiography provided no benefit over a delayed or selective strategy with respect to the 30-day risk of death from any cause.

Published
2021

39. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Author

Zelniker, Thomas A., primary, Ardissino, Maddalena, additional, Andreotti, Felicita, additional, O’Donoghue, Michelle L., additional, Yin, Ophelia, additional, Park, Jeong-Gun, additional, Murphy, Sabina A., additional, Ruff, Christian T., additional, Lanz, Hans J., additional, Antman, Elliott M., additional, Braunwald, Eugene, additional, Giugliano, Robert P., additional, and Merlini, Piera Angelica, additional

Published
2021
Full Text
View/download PDF

40. Feasibility of CardioSecur®, a Mobile 4-Electrode/22-Lead ECG Device, in the Prehospital Emergency Setting

Author

Spaich, Sebastian, Kern, Hanna, Zelniker, Thomas A., Stiepak, Jan, Gabel, Michael, Popp, Erik, Katus, Hugo A., and Preusch, Michael R.

Subjects
STEMI, user-friendliness, myocardial infarction, ECG, cardiovascular diseases, Cardiovascular Medicine, electrocardiogram, Original Research, acute coronary syndrome, feasibility
Abstract

Background: This study explores the application of CardioSecur® (CS-ECG), a hand-held 4-electrode/22-lead ECG-device, in comparison with conventional 12-lead electrocardiogram (c12L-ECG) in patients with acute chest pain in the prehospital emergency setting. Methods: CS-ECG systems were provided for two physician-staffed emergency ambulances and parallel recordings of c12L-ECG and CS-ECG were obtained from all patients with acute chest pain. Treating emergency physicians were asked to evaluate the CS-ECG system with a standardized questionnaire. Following study completion, acquired ECGs were analyzed separately by two independent cardiologists blinded to all other medical records. Results: Over a period of 20 months a total of 203 patients were included in our study. According to a standardized questionnaire, 79% of emergency medical professionals preferred application of CS-ECG, with 87% of teams judging CS-ECG to be beneficial for patients. Morover, 79% of physicians reported a reduction in time to definitive diagnosis with implementation of CS-ECG. The majority of professional users attested user-friendliness and feasibility of CS-ECG in terms of easy general handling (94%), application (93%), and placement of electrodes (98%). During prehospital triage, both c12L-ECG and CS-ECG correctly identified 31 (91%) patients with ST-elevation myocardial infarction (STEMI). Conclusion: In this first pilot study, implementation of the CardioSecur®-ECG system in the prehospital emergency setting demonstrated feasibility and user-friendliness so that emergency teams generally preferred CS-ECG to c12L-ECG. Diagnostic yield of CS-ECG was similar to c12L-ECG recordings.

Published
2020

41. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

Author

Zelniker, Thomas A., primary, Morrow, David A., additional, Mosenzon, Ofri, additional, Goodrich, Erica L., additional, Jarolim, Petr, additional, Murphy, Sabina A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John, additional, Bode, Christoph, additional, Lewis, Basil S., additional, Gause‐Nilsson, Ingrid, additional, Langkilde, Anna Maria, additional, Fredriksson, Martin, additional, Raz, Itamar, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2020
Full Text
View/download PDF

45. ORAL AB AGORA1362Cardiac Involvement in Patients With Different Rheumatic Disorders1366Gender differences in the development of cardiac complications: a multicentric prospective study in a large cohort of thalassemia major patients1646Comparison of T1-mapping, T2-weighted and contrast-enhanced cine imaging at 3.0T CMR for diagnostic oedema assessment in ST-segment elevation myocardial infarction1375Evaluation of Tissue Changes in Remote Noninfarcted Myocardium after Acute Myocardial Infarction using T1-mapping1377Right ventricular long axis strain – The prognostic value of a novel parameter in non-ischemic dilated cardiomyopathy using standard cardiac magnetic resonance imaging1389The role of the right ventricular insertion point in heart failure patients with preserved ejection fraction: Insights from a cardiovascular magnetic resonance study1398Myocardial fibrosis associates with B-type natriuretic peptide levels and outcomes more than wall stress1478Prognostic Value of Pulmonary Blood Volume by Contrast-Enhanced Magnetic Resonance Imaging in Heart Failure Outpatients – The PROVE-HF Study1370Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary1509Influence of non-invasive hemodynamic CMR parameters on maximal exercise capacity in surgically untreated patients with Ebstein's anomaly1356Proximal aortic stiffening in Turner patients is more pronounced in the presence of a bicuspid valve. A segmental functional MRI study1503Flow pattern and vascular distensibility of the pulmonary arteries in patients after repair of tetralogy of Fallot. Insights from 4D flow CMR1516Myocardial deformation characteristics of the systemic right ventricle after atrial switch operation for transposition of the great arteries1633Three-dimensional vortex formation in patients with a Fontan circulation: evaluation with 4D flow CMR1483Mitral valve prolapse: arrhythmogenic substrates by cardiac magnetic imaging1596Increased local wall shear stress after coarctation repair is associated with descending aorta pulse wave velocity: evaluation with CMR and 4D flow1636Three-dimensional wall shear stress assessed by 4Dflow CMR in bicuspid aortic valve disease1464Cardiac Amyloidosis and Aortic Stenosis – The Convergence of Two Aging Processes1630Blood T1 variability explained in healthy volunteers: an analysis on MOLLI, ShMOLLI and SASHA1408Myocardial deformation on CMR predicts adverse outcomes in carcinoid heart disease - a new marker of risk1492Myocardial Perfusion Reserve and Global Longitudinal Strain in Early Rheumatoid Arthritis1500Exercise CMR to differentiate athlete's heart from patients with early dilated cardiomyopathy1559Real-Time, x-mri guidance to optimise left ventricular lead placement for delivery of cardiac resynchronisation therapy1560The role of Cardiac magnetic resonance imaging in patients undergoing ablation for ventricular tachycardia- Defining the substrate and visualizing the outcome1590Impact of cardiovascular magnetic resonance on clinical management and decision-making of out of hospital cardiac arrest survivors with inconclusive coronary angiogram1561Detection of coronary stenosis at rest using Oxygenation-Sensitive Magnetic Resonance Imaging

Author

J. Ranjit Arnold, A. Baritussio, S. Oebel, Jonathan Behar, G. Claessen, G.J. Fent, B. Liu, Stefania Rosmini, João L. Cavalcante, Lydia Dux-Santoy, I. Nederend, Manuel De Lazzari, Vivian P. Kamphuis, B.E.U. Burkhardt, Beate Ruecker, Daniel G.H. Devos, Christian Meierhofer, Peter Bernhardt, F. Ricci, Aatif Sayeed, Andreas A. Kammerlander, Nisha Arenja, P. Stefan Biesbroek, Sheraz A. Nazir, A. Meloni, S. Greulich, D. Kitterer, J. Latus, J. Henes, R. Kurmann, S. Gloekler, A. Wahl, S. Buss, H. Katus, M. Bobbo, M. Lombardi, N. Braun, M.D. Alscher, U. Sechtem, H. Mahrholdt, M.G. Neri, P. Preziosi, E. Grassedonio, N. Schicchi, P. Keilberg, S. Pulini, E. Facchini, V. Positano, A. Pepe, Abhishek Shetye, Jamal N. Khan, Anvesha Singh, Prathap Kanagala, Daniel Swarbrick, Gaurav Gulsin, Matthew Graham-Brown, Iain Squire, Anthony Gershlick, Gerry P. McCann, Raquel P. Amier, Paul F.A. Teunissen, Lourens F.H.J. Robbers, Aernout M. Beek, Albert C. van Rossum, Mark B.M. Hofman, Niels van Royen, Robin Nijveldt, Johannes H Riffel, Charly Noel Djiokou, Florian Andre, Thomas Fritz, Manuel Halder, Zelniker Thomas, Grigorios Korosoglou, Hugo A Katus, Sebastian J Buss, Marianne L. Schwaiger, Franz Duca, Stefan Aschauer, Beatrice A. Marzluf, Caroline Zotter-Tufaro, Daniel Dalos, Stefan Pfaffenberger, Diana Bonderman, Julia Mascherbauer, Yaron Fridman, Brianne Hackman, Ajay Kadakkal, Maren Maanja, Hussein Abu Daya, Timothy C. Wong, Erik B. Schelbert, A. Barison, G. Todiere, R. Gaeta, S. Galllina, M. Emdin, R. De Caterina, G.D. Aquaro, Dominik Buckert, Nils Dyckmanns, Wolfgang Rottbauer, Andreas Kühn, Nerejda Shehu, Jan Müller, Heiko Stern, Peter Ewert, Sohrab Fratz, Manfred Vogt, Katya De Groote, Danilo Babin, Laurent Demulier, Yves Taeymans, Jos J. Westenberg, Luc Van Bortel, Patrick Segers, Eric Achten, Jean De Schepper, Ernst Rietzschel, Julia Geiger, Malek Makki, Barbara Burkhardt, Christian J. Kellenberger, Emanuela R. Valsangiacomo Buechel, C.J. Kellenberger, J. Geiger, B. Ruecker, E.R. Valsangiacomo Buechel, Mohammed S.M. Elbaz, Lucia J.M. Kroft, Rob J. van der Geest, Albert de Roos, Nico A. Blom, Jos J.M. Westenberg, Arno A.W. Roest, Alberto Cipriani, Angela Susana, Stefania Rizzo, Benedetta Giorgi, Lacognata Carmelo, Emanuele Bertaglia, Barbara Bauce, Domenico Corrado, Gaetano Thiene, Martina Perazzolo Marra, Cristina Basso, Sabino Iliceto, A.A.W. Roest, P.J. van den Boogaard, A.D.J. ten Harkel, J.C.N. de Geus, L.J.M. Kroft, A. de Roos, J.J.M. Westenberg, Raquel Kale, Gisela Teixido-Tura, Giuliana Maldonado, Marina Huguet, David Garcia-Dorado, Artur Evangelista, Jose Rodriguez-Palomares, Shasank Rijal, John T. Schindler, Thomas G. Gleason, Joon S. Lee, Heerajnarain Bulluck, Thomas A Treibel, Anish Bhuva, Amna Abdel-Gadir, Veronica Culotta, Ahmed Merghani, Viviana Maestrini, Anna S Herrey, Peter Kellman, Charlotte Manisty, James C Moon, M.K. Hayer, S. Baig, T. Shah, S.J. Rooney, N.C. Edwards, R.P. Steeds, P. Garg, P. Swoboda, L.E. Dobson, T.A. Musa, J.F. Foley, P. Haaf, J.P. Greenwood, S. Plein, F. Schnell, J. Bogaert, S. Dymarkowski, N. Pattyn, P. Claus, J. Van Cleemput, A. La Gerche, H. Heidbuchel, Daniel Toth, Sabrina Reiml, Maria Panayiotou, Simon Claridge, Tom Jackson, Manav Sohal, Jessica Webb, Mark O'Neill, Alexander Brost, Peter Mountney, Reza Razavi, Kawal Rhode, Christopher Aldo Rinaldi, A. Arya, S. Hilbert, A. Bollmann, G. Hindricks, C. Jahnke, I. Paetsch, B. Dinov, M. Perazzolo Marra, A. Ghosh Dastidar, J. Rodrigues, A. Zorzi, A. Susana, A. Scatteia, E. De Garate, G. Mattesi, J. Strange, D. Corrado, C. Bucciarelli-Ducci, Michael Jerosch-Herold, Theodoros D. Karamitsos, Jane M. Francis, Paul Bhamra-Ariza, Rizwan Sarwar, Robin Choudhury, Joseph B. Selvanayagam, and Stefan Neubauer

Subjects
medicine.medical_specialty, business.industry, Bicuspid valve, Internal medicine, Cardiology, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Cardiology and Cardiovascular Medicine, business, Stiffening
Published
2016

46. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58.

Author

Zelniker, Thomas A., Morrow, David A., Mosenzon, Ofri, Goodrich, Erica L., Jarolim, Petr, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John, Bode, Christoph, Lewis, Basil S., Gause‐Nilsson, Ingrid, Langkilde, Anna Maria, Fredriksson, Martin, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Subjects
*DAPAGLIFLOZIN, *HEART failure, *TYPE 2 diabetes, CARDIOVASCULAR disease related mortality
Abstract

Aims: Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels. Methods and results: This was a pre‐specified biomarker study from DECLARE‐TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin. Baseline NT‐proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT‐proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35–165] and 10.2 pg/mL (IQR 6.9–15.5), respectively. Patients with higher NT‐proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT‐proBNP: 4‐year Kaplan–Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P‐trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT‐proBNP (P‐interaction 0.72) or hsTnT quartiles (P‐interaction 0.93). Given their higher baseline risk, patients with NT‐proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT‐proBNP 1.9% vs. 0%, P‐interaction 0.010; hsTnT 1.8% vs. 0.1%, P‐interaction 0.026). Conclusion: Patients with type 2 diabetes mellitus and higher NT‐proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT‐proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. 244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

Author

RAZ, ITAMAR, primary, WIVIOTT, STEPHEN D., additional, YANUV, ILAN, additional, ROZENBERG, ALIZA, additional, ZELNIKER, THOMAS A., additional, CAHN, AVIVIT, additional, HEERSPINK, HIDDO L., additional, DWYER, JAMIE P., additional, GOODRICH, ERICA, additional, BHATT, DEEPAK L., additional, LEITER, LAWRENCE A., additional, MCGUIRE, DARREN K., additional, WILDING, JOHN P., additional, GAUSE-NILSSON, INGRID ANNA, additional, FREDRIKSSON, MARTIN, additional, JOHANSSON, PETER A., additional, LANGKILDE, ANNA MARIA, additional, SABATINE, MARC S., additional, and MOSENZON, OFRI, additional

Published
2019
Full Text
View/download PDF

48. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53

Author

Zelniker, Thomas A, primary, Morrow, David A, primary, Mosenzon, Ofri, primary, Gurmu, Yared, primary, Im, Kyungah, primary, Cahn, Avivit, primary, Raz, Itamar, primary, Steg, Philippe Gabriel, primary, Leiter, Lawrence A, primary, Braunwald, Eugene, primary, Bhatt, Deepak L, primary, and Scirica, Benjamin M, primary

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results